A distinction is often made between interfering antibodies of iatrogenic and noniatrogenic origin. In people, iatrogenic interfering antibodies stem from in vivo diagnostic or therapeutic treatments with monoclonal mouse antibodies. Noniatrogenic interfering antibodies include heterophilic antibodies and rheumatoid factors that occasionally cross-react with assay antibodies. 6, 7 Heterophilic antibodies are found in people with no history of in vivo antibody treatments, and rheumatoid factors are autoantibodies, usually of the IgM class.
Although most research on immunoassay interference involves human medicine studies, a few recent studies have shown that interfering antibodies in canine serum affected BNP (B-type natriuretic peptide), and possibly AMH (anti-M€ ullerian hormone) assay results. 8, 9 Despite the potentially harmful impact on patient care, knowledge about antibody interference within veterinary medicine remains very limited. If the situation is comparable to that in human medicine, antibody interference might be a problem in veterinary medicine as well. Screening studies have shown that interfering antibodies can perturb the testing of several analytes, 10, 11 and recent case reports of human antibody interference in multiple hormone assays have been published. [12] [13] [14] [15] To screen a population for interfering antibodies, a method that is customized to detect antibody interference is needed. Often a 2-site immunoassay is used, with a combination of capture and detection antibodies that do not cross-link with any known substance so that only molecules with irregular cross-linking abilities (ie, interfering antibodies) can generate a signal. 7 There are several ways of eliminating interfering antibodies in a sample. Assay manufacturers often incorporate mammalian immunoglobulin in the sample incubation buffer, attempting to neutralize anti-mammalian antibodies. Another option is to base the assay on reagents that interfering antibodies do not react with, such
as chicken IgY, which shows no cross-reactivity with mammalian IgG 16 and has been shown to eliminate the effects of iatrogenic and noniatrogenic interfering antibodies in human samples. 16, 17 The aims of this study were to set up a species-independent interference assay for detecting interfering antibodies, to use it to screen a population of dogs and cats visiting an animal hospital, and to evaluate if the interference can be eliminated by using an assay based on chicken reagents.
| MATERIALS AND METHODS

| Animals
The serum used in this study was collected from dogs and cats admitted to the University Animal Hospital in Uppsala, Sweden.
Written consent was obtained from owners of all animals, and the study was performed in accordance with national animal welfare regulations (SJVFS 2015:38) . Serum was frozen at À20°C for up to 6 months until analysis. All samples were thawed at room temperature (RT) and vortex-mixed before analysis. Exclusion criteria were clearly visible signs of hemolysis, bilirubinemia, or lipemia. No inclusion criteria were applied. 
| Interference assay
| Statistical analysis
All statistical analyses were performed using the R Software version 3.3.3 (R Core Team, Vienna, Austria).
Differences in prevalence, sex, breed, neutering status, and diagnosis between the interference-positive and interference-negative groups (for both dogs and cats) were tested using a 2-sample test for equality of proportions (2-tailed). Differences in age between
positive and negative groups were tested with the Wilcoxon ranksum test because the age data were not normally distributed.
In the interference elimination study, the mouse IgG and chicken
IgY-assayed samples were compared using the Wilcoxon signed-rank test. Statistical significance was set at P < .05.
3 | RESULTS
| Dogs
The screening included 369 samples from 320 individual dogs. Multiple samples were assayed for 42 of the dogs; 36 of them twice, 5 of them 3 times, and 1 of them 4 times. All multiple samples were collected on different occasions. Ninety-six different breeds were represented. The median age of the dogs was 6.5 years, interquartile range (IQR) 3-9 years. There were 130 intact males, 37 castrated males, 107 intact females, and 46 spayed females. The dogs were allocated into 13 different categories based on diagnosis or reason for admittance to the hospital (Table 1) .
Of the included dogs, 77 (24.1%) were treated with immunosuppressant medication such as glucocorticoids (n = 74), ciclosporin (n = 2), or mycophenolic acid (n = 1) at the time of sampling or within 1 month prior to sampling. Five of the dogs received blood transfusions at some point prior to sampling.
| Cats
We Disease categories are sorted in descending order according to number of dogs. Immunosuppressants include glucocorticoids (n = 74), ciclosporin (n = 2), and mycophenolic acid (n = 1).
a Clinical signs not clearly related to a specific organ (eg, "lethargy" or "inappetence").
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| 207 spayed females. The diagnostic classification rationale was the same as for dogs, but there were no cats diagnosed with cardiovascular disorders or systemic autoimmune disease, resulting in 11 final categories (Table 2) . Twenty-six of the included cats (11.9%) were treated with glucocorticoids at the time of sampling or within 1 month prior to sampling.
| Interference ELISA
Using a 4-parameter logistic curve-fitting model (4PL), a standard curve was obtained (Figure 1 ). The cutoff point was determined by calculating the mean OD of the duplicates of the seventh point on the standard curve. It thus corresponds to a low, reproducible signal originating from interfering antibody reactivity. For each run, the cutoff point was required to be greater than the assay LoD (limit of detection), as determined by the formula LoD = 0-calibrator + 2 SD (where 25 repeat measurements of the 0-calibrator were made). The inter-assay CV for the cutoff point was 9.1%.
Acceptable intra-assay CV for all controls, calibrators, and samples was set to <20%.
20
A relative OD value for each sample was calculated by dividing the mean OD of the sample by the cutoff value. The cutoff limit for a positive result was >1 for all runs. Similarly, the positive control was required to be >1 and the negative control <1 in each run.
| Interfering antibodies in dogs and cats
In total, 9% of the dogs (28/320) and 5% of the cats (10/218) were interference-positive. There was no significant difference in the prevalence of interference between dogs and cats (P = Clinical signs not clearly related to a specific organ (eg, "lethargy" or "inappetence"). were treated with glucocorticoids within a month prior to sampling.
There was no significant difference in age, sex, breed, neutering status, or diagnostic category between interference-positive and interference-negative dogs and cats. 
| DISCUSSION
We present an in-house species-independent ELISA for detecting with the reported transience of heterophilic antibodies. 26 The high degree of repeatability suggests that various potential error sources F I G U R E 1 A representative standard curve from one of the ELISA runs in the screening experiment. The x-axis represents an assumed concentration of the standard. Point 7 corresponds to the positive cutoff level. Points 1-6 were included to ensure that the assay consistently measured interference of varying degrees. The curve assumes a 1 mg/mL concentration of anti-mouse IgG in the stock solution. The 0-concentration of the standard has been entered as 0.01 to fit on the curve. 4PL, 4-point logistic regression F I G U R E 2 Dog (n = 369) and cat (n = 263) samples were screened with a 2-step sandwich ELISA using nonimmunized mouse IgG as the capture antibody. An HRP-conjugated mouse anti-CEA antibody was used as the detection antibody. Cutoff level is indicated by the dashed horizontal line. The results are presented on a relative scale and calculated according to the formula: (mean sample OD)/(mean cutoff OD). There was no significant difference in prevalence of interference between dogs and cats (P = .06) such as environmental factors in the laboratory and operator errors did not influence the results significantly. However, there was no statistical analysis performed on this data because of lack of statistical power (only 3 positive subjects contributed multiple samples).
The strongest indication that the interference was caused by interfering antibodies comes from the results of the elimination experiment.
We were able to demonstrate a significant decrease in signal and elimination of reactivity in all 19 samples studied by switching the capture antibody from mouse IgG to chicken IgY.
Using chicken IgY as the capture antibody in a 2-step sandwich ELISA has previously been shown to eliminate antibody interference in human serum. 16, 17 The biological explanation is that mammalian and avian species are phylogenetically different and their antibodies do not cross-react. 27 Because interference elimination using avian antibodies specifically targets interfering antibodies, the results indi- ies. 28 The stacking creates a tight space in multiple binding sites, which enhances binding and increases avidity. If the stacking is a prerequisite for optimal heterophilic antibody binding conditions, they are likely to be prone to high CV, because the physical orientation of capture antibodies and formation of stacks can be assumed to be unique for each microtiter well. Multiple runs and a high CV re-assaying routine in the elimination experiment would probably be a good strategy for dealing with this problem but would require more sample material than available.
The interfering antibodies in the positive samples are most likely to be of noniatrogenic origin. Iatrogenic antibodies are unlikely to be present because the administration of monoclonal antibody therapy in veterinary practice is rare. However, dogs and cats share environments and lifestyles with human beings, and thus they also share routes believed to induce heterophilic antibodies. These routes include direct physical contact with other species as well as indirect contact via vaccinations and food ingestion. 29, 30 The interference assay tested reactivity toward mouse IgG, but it is possible that the test-positive subjects had been immunized by other species because cross-reactivity between IgG from different mammalian species is known to happen. 31, 32 We reviewed journal data of the screened dogs and cats to identify possible risk factors for interference, but we found no significant correlation with parameters such as age, sex, breed, neutering status, and diagnosis. These results are consistent with the unknown and essentially "random" etiology of heterophilic
antibodies. This argument is based on the assumption that the mechanism behind heterophilic antibody formation does not differ between species.
It is also possible that rheumatoid factors account for some of the detected interference. Age, gender, and autoimmunity are suggested risk factors for rheumatoid factor interference in people 10 due to the overrepresentation of women, 33 the increasing prevalence of rheumatoid arthritis with age, 33, 34 and the high prevalence of rheumatoid factors in patients with rheumatoid arthritis (estimated to be 70%). However, rheumatoid factors can also be found in approximately 5%-10% of the general human population. 35 Rheumatoid factor testing has sometimes been used for diagnosing rheumatoid arthritis in dogs, but prevalence data are uncertain because of lack of test standardization. 36 Immune-mediated joint disorders are rare in cats, but rheumatoid factor tests have mostly been positive in reports of cats with rheumatoid-like arthritis. 37, 38 The fact that we saw no association between interference and known risk factors might be due to low statistical power. Only 9
dogs (all of which tested negative for interference) were classified with autoimmune disease, and all were treated with glucocorticoids.
Because glucocorticoid administration has been shown to cause overall immunoglobulin deficiency, 39,40 the treatments might also affect the risk of antibody-induced interference. However, dogs and cats treated with immunosuppressant medication were not underrepresented among the interference-positive test subjects. Unfortunately, we were not able to account for the dose and duration of treatment because this information was not available in all cases.
Finally, because we do not have access to a full medical history for all dogs and cats, there might be chronic underlying diseases present 
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